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Objective: To assess patient preferences for treatment-related beneﬁts and risks associated with the use
of nonsteroidal anti-inﬂammatory drugs (NSAIDs) in the management of osteoarthritis (OA).
Design: Using a chronic-illness panel in the United Kingdom, patients 45 years or older with a self-
reported diagnosis of OA were eligible to participate in the study. Patient preferences were assessed
using a discrete-choice experiment that compared hypothetical treatment proﬁles of beneﬁts and risks
consistent with NSAID use. Beneﬁt outcomes (ambulatory pain, resting pain, stiffness, and difﬁculty
doing daily activities) were presented on a 0-to-100 mm scale. Risk outcomes (bleeding ulcer, stroke, and
myocardial infarction [MI]) were expressed as probabilities over a ﬁxed time period. Each patient
answered 10 choice tasks comparing different treatment proﬁles. Preference weights were estimated
using a random-parameters logit model.
Results: Final sample included 294 patients. Patients ranked reductions in ambulatory pain and difﬁculty
doing daily activities (both: 6.32; 95% conﬁdence interval [CI]: 5.0e7.6) as the most important beneﬁt
outcomes, followed by reductions in resting pain (2.80; 95% CI: 1.8e3.8) and stiffness (2.65; 95% CI:
0.9e4.4). Incremental changes (3%) in the risk of MI or stroke were assessed as the most important risk
outcomes (10.00; 95% CI: 8.2e11.8; and 8.90; 95% CI: 7.3e10.5, respectively).
Conclusion: Patients ranked ambulatory pain as a more important beneﬁt than resting pain; likely due to
its impact on ability to do daily activities. For a 25-mm reduction, patients were willing to accept four
times the risk of MI in ambulatory pain vs resting pain.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common form of arthritis,
characterized by pain, swelling, and a sensation of stiffness in the
joints. It can occur in any synovial joint but most commonly affects
the hips, knees, hands, and lumbar or cervical spine. The onset of
symptomatic OA usually occurs in individuals over 50 years of age.
OA affects approximately 8.5 million individuals in the United
Kingdom (UK)1.
There is currently no cure for OA, and treatment is palliative.
Nonselective, nonsteroidal anti-inﬂammatory drugs (NSAIDs) and.B. Hauber, Health Preference
rive, PO Box 12194, Research
49; Fax: 1-919-541-7222.
s Research Society International. Pparacetamol are the most commonly used treatments for the pain
and inﬂammation of OA2e5. The most common side effects of
NSAIDs and paracetamol are gastrointestinal (GI) in nature and
include nausea, dyspepsia, and ulcers. A newer class of NSAIDs,
selective cyclooxygenase-2 (COX-2) inhibitors, has been developed
and is associated with a lower rate of GI side effects compared with
older, more commonly used nonselective NSAIDs. Recently,
nonselective NSAIDs and selective COX-2 inhibitors have been
linked to risks of thrombotic cardiovascular events (myocardial
infarctions [MIs] and strokes)6e13. Despite these risks, NSAIDs and
selective COX-2 inhibitors are still widely prescribed for patients
with OA14,15.
In order tomake an informed decision, patients must be advised
of both the beneﬁts and risks of medications. However, Katz et al.16
found that disclosure of side effects of NSAIDs to patients is limited
and that patients initiating a new prescription for an NSAID, whoublished by Elsevier Ltd. All rights reserved.
Table I
Beneﬁcial and negative attributes and their different levels used in the survey
instrument
Attribute labels Abbreviated label Levels*
Pain while moving around
1 h after taking the
medicine
Ambulatory pain None (0 mm)
Mild (25 mm)
Moderate (50 mm)
Severe (75 mm)
Pain while sitting, lying
down, or sleeping 1 h
after taking the medicine
Resting pain None (0 mm)
Mild (25 mm)
Moderate (50 mm)
Severe (75 mm)
Stiffness 1 h after taking the
medicine
Stiffness None (0 mm)
Mild (25 mm)
Moderate (50 mm)
Severe (75 mm)
Difﬁculty doing your daily
activities 1 h after taking
the medicine
Difﬁculty doing
daily activities
None (0 mm)
Mild (25 mm)
Moderate (50 mm)
Severe (75 mm)
Chance of a bleeding ulcer
requiring an operation
within the next year
because of the medicine
Ulcer risk None
10 out of 1,000 (1.0%)
50 out of 1,000 (5.0%)y
100 out of 1,000 (10.0%)y
Additional chance of a heart
attack or stroke within
the next 5 years because
of the medicinez
Heart-attack risk/
stroke risk
No chance
5 out of 1,000 (0.5%)
15 out of 1,000 (1.5%)
30 out of 1,000 (3.0%)
* On a 0-to-100 mm visual analog scale, unless stated otherwise.
y Not relevant for the average OA population.
z Heart-attack and stroke risks are both cardiovascular risks and could not be
included at the same time because they are inherently correlated. In the discrete-
choice survey, heart-attack risk was shown half the time, and stroke risk was
shown the other half.
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addition, Kopec et al.17 found that risk tolerance for OAmedications
varied widely among patients but that clinical, sociodemographic,
and psychological characteristics did not explain this variation.
Regulatory authorities routinely appraise a drug’s safety and
efﬁcacy as part of the approval process; however, these safety and
efﬁcacy tradeoffs are not made using directly comparable metrics,
as no standard quantitative method currently exists for weighing
the relative preference of treatment beneﬁts and risks among
relevant stakeholders. Patient-preference methods such as
discrete-choice experiments have been used increasingly in recent
years to quantify the relative importance of the beneﬁts and risks of
different drugs to patients and other stakeholders in the drug
approval process18e20. The primary objective of this study was to
quantify beneﬁt-risk preferences for patients with OA with respect
to medication outcomes associated with nonselective NSAIDs and
selective COX-2 inhibitors. Speciﬁcally, our objective was to esti-
mate OA patients’ risk tolerance for serious adverse events
including bleeding ulcer, MI, and stroke. It is intended that this
information be used to inform evaluations of new and existing
NSAID treatments.
Method
Study sample
The target sample size in this study was 300 respondents.
Minimum sample sizes in discrete-choice experiments depend on
a number of criteria, including the question format, the complexity
of the choice task, the desired precision of the results, and the need
to conduct subgroup analyses21. Researchers commonly apply
a rule of thumb such as that proposed by Orme22. Most discrete-
choice experiments in health that include numbers of attributes
and levels similar to those in this study use sample sizes between
100 and 300 respondents23.
Respondents were recruited via e-mail invitation from Harris
Interactive’s (Rochester, New York, USA) online chronic-illness
panel in the UK. Adults are recruited into the panel and agree to
take surveys for which they receive points that can be redeemed for
merchandise. After enrollment, panelists are screened for a number
of diagnosed chronic illnesses, including OA. Even though the panel
is representative of the general UK population, the panel members
who were eligible and consented to participate in our survey may
not be representative of the OA patient population in the UK.
Participating patients were required to have a self-reported
physician’s diagnosis of OA and to be a UK resident aged 45 years
or older. Harris Interactive administered the 25-min online survey
in August 2009. The survey did not require review by the National
Research Ethics Committee (NRES) because this study was neither
interventional nor observational and because respondents were
not recruited through the National Health Service (NHS). The
survey was approved by RTI International’s Ofﬁce of Research
Protection and Ethics (Research Triangle Park, North Carolina, USA),
and patients were required to provide online informed consent
prior to participating in the survey.
Discrete-choice experiments
Discrete-choice experiments (also known as choice-format
conjoint analysis) are used to quantify decision criteria for attri-
butes of health and health care23,24 and patient preferences in
OA25e27. Discrete-choice experiments are a systematic method of
eliciting tradeoffs to quantify the relative importance patients
assign to various treatment attributes and outcomes. Discrete-
choice experiments are based on the premise that medicalinterventions are composed of a set of attributes and that the ability
of a particular intervention to satisfy the needs or wants of an
individual is a function of these attributes18,21,28. In the experiment,
respondents are presented with a series of questions in which they
are asked to choose a preferred alternative from a set of hypo-
thetical treatment proﬁles. These treatment proﬁles vary by levels
of treatment attributes.
Survey instrument
We reviewed package inserts and clinical-trial literature and
consulted with clinical experts to identify the most common
beneﬁt outcomes and most serious adverse events associated with
nonselective NSAIDs and selective COX-2 inhibitors. We identiﬁed
seven attributesdfour beneﬁts and three risksdto describe the OA
medication-attribute proﬁles in this study (Table I). Each of the
medication-related beneﬁts (reductions in ambulatory pain, resting
pain, stiffness, and difﬁculty doing daily activities) and risks
(bleeding ulcer, stroke, and MI), were varied across four possible
levels. The range of levels of each attribute was intended to meet
three criteria: (1) the range of levels should span the clinically
relevant range of outcomes that has been seen or might be ex-
pected to be seen in clinical trials or clinical practice, (2) differences
in levels should encompass the range of improvements in efﬁcacy
outcomes or the range of increases in adverse-event outcomes that
potentially could be seen in clinical trials or clinical practice, and (3)
the range of levels should encompass the maximum range over
which respondents arewilling to accept tradeoffs among attributes.
The beneﬁts were developed to correspond to three domains of
the Western Ontario and McMaster (WOMAC) Index of OA (pain,
stiffness and physical function) because these domains are
commonly used as clinical-trial endpoints in OA studies29. Using
clinician recommendations, we considered two independent pain
attributes, resting pain and ambulatory pain, because these two
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(MI and stroke) and GI risk (bleeding ulcer) were included because
these are among the most worrisome severe adverse events in this
therapeutic class.
Descriptions of these attributes were conﬁrmed with one-on-
one, face-to-face interviews with 10 patients in the UK. During
the interviews, patients were asked to “think aloud” as they
completed the draft survey instrument. Patients also were asked
a series of debrieﬁng questions to determine whether they
understood the deﬁnitions and instructions, accepted the hypo-
thetical context of the survey, thought any relevant attributes
necessary to make treatment choices were omitted, and were able
to complete the treatment-choice questions in the survey instru-
ment as instructed30. The range of levels of the GI risk over which
respondents were willing to trade, as determined in the face-to-
face interviews, was much wider than the clinically relevant range.
In each treatment-choice question, patients were asked to
choose between two hypothetical medication proﬁles (Fig. 1). Each
hypothetical medication proﬁle was deﬁned by varying levels of the
seven attributes. The experimental design used to construct the
treatment-choice questions utilized the D-optimal main-effects
criteria using GAUSS Version 8.0 (Aptech Systems, Inc., BlackFig. 1. Example of a treatment-choice question presented to patients.a
aHeart-attack and stroke risks are both cardiovascular risks and could not be included at the
attack risk was shown half the time, and stroke risk was shown the other half.Diamond, Washington, USA)31e35. The result was 30 treatment-
choice questions that were equally divided among three versions
of the survey, i.e., each version contained 10 treatment-choice
questions. Each patient was randomly assigned to one of the
three versions. Within each version, the order of the treatment-
choice questions was randomized across patients, but the order
of the attributes was not randomized in the treatment-choice
questions. No ﬁxed treatment-choice questions were included.
Prior to answering the treatment-choice questions, patients were
asked to assume that all medications were tablets and that there
would be no difference in costs between the two medications.
Statistical analysis
The pattern of patients’ choices was analyzed using a random-
parameters logit model. In this model, the dependent variable
was discrete treatment choice; the explanatory variables included
the levels of the attributes shown in Table I. The resulting
importance-weight parameter estimates quantiﬁed the relative
importance of each attribute level36e38. All analyses were con-
ducted using NLOGIT 4.0 (Econometric Software, Inc., Plainview,
New York, USA).same time because they are inherently correlated. In the discrete-choice survey, heart-
Table II
Demographic and clinical characteristics of the participating OA patients
Category Number of
respondents
(N ¼ 289)
Percentage of
respondents
Gender
Male 101 34.9
Female 188 65.1
Age, mean (SD), years 59 (8.4) N/A
65 or younger 221 76.5
Older than 65 68 23.5
Marital status
Married 182 63.0
Widowed 19 6.6
Divorced or separated 59 20.4
Single 23 8.0
Other 8 2.0
Education
High school or less 138 47.8
Further/vocational education 104 36.0
University degree or higher 47 16.2
Race or ethnicity
White 286 99.0
Other 3 1.0
Employment status
Employed 90 31.1
Retired 118 40.8
Homemaker 19 6.6
Unemployed 62 21.5
How long has it been since your symptoms were ﬁrst diagnosed as OA by
a doctor?
Less than 1-year ago 23 8.0
At least 1-year ago, but less
than 2 years ago
38 13.1
At least 2 years ago, but less
than 5 years ago
64 22.1
At least 5 years ago, but
less than 10 years ago
88 30.5
More than 10 years ago 76 26.3
In the last 12 months, how many times have you seen a doctor or other health
care professional for your OA?
None 37 12.8
1e3 times 141 48.8
4e6 times 64 21.1
7e9 times 25 8.7
10e12 times 11 3.8
More than 12 11 3.8
Do you currently take any prescription medicines to treat your OA?
Yes 219 75.8
No 70 24.2
Do you take any over-the-counter medicines to treat your OA (medicines you
bought yourself without a prescription)?
Yes 139 48.1
No 150 51.9
Do you have high blood pressure?
Yes 141 48.8
No 148 51.2
Are you currently taking any prescription medicines to treat heartburn,
indigestion, acid reﬂux, or other stomach problems?
Yes 103 35.6
No 186 64.4
Have you ever had a heart attack?
Yes 17 5.9
No 272 94.1
Have you ever had a stroke?
Yes 15 5.2
No 274 94.8
Baseline level of ambulatory
pain, mean (SD), 0e100 scale
65.3 (25.5) N/A
Baseline level of resting pain,
mean (SD), 0e100 scale
52.5 (30.2) N/A
Baseline level of stiffness,
mean (SD), 0e100 scale
64.7 (25.1) N/A
Baseline level of difﬁculty
doing daily activities,
mean (SD), 0e100 scale
66.3 (28.0) N/A
N/A ¼ not applicable.
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doing daily activities and the level of ambulatory pain as being
highly correlated. Therefore, we included ambulatory pain, but not
difﬁculty doing daily activities in the analysis. The reported impor-
tance weights for ambulatory pain thus incorporated the combined
effect of pain severity and the corresponding limitation on daily
activities. Although importance weights for the medication-related
ulcer risk varied from 0% to 10%, we used only the most relevant
values for the OA population (0%, 1%, and 2.5%) in interpreting the
results. We included the range over which patients would trade off
medication-related ulcer risk against other attributes, which was
wider than the range that was most likely to occur in the clinical
setting. We used a linear interpolation between 1% and 5% to
calculate the importance weight for 2.5%. We also conducted
subgroup analysis using interaction terms, split-sample analyses,
and latent-class analysis to test for differences in preferences based
on sociodemographic factors and self-reported severity of OA.
The choice model results then were used to estimate a mean
overall importance score for each attribute as well as patients’ risk
tolerance, or maximum acceptable risk (MAR), that would be
tolerated for improvements in the beneﬁt obtained. The overall
importance scores were estimated as the difference in the param-
eter estimates between the best and worst levels for each attribute
and then scaled so that the most important attribute had a mean
relative importance score of 10. MAR is the meanmaximum level of
treatment-related risk patients are willing to accept for a given
improvement in beneﬁt outcomes. It is calculated as the change in
risk of a given adverse event (bleeding ulcer, MI, or stroke) that
would exactly offset the perceived beneﬁt of a given improvement
in beneﬁt (ambulatory pain, resting pain, stiffness, or difﬁculty
doing daily activities).
Results
Patient sample characteristics
Harris Interactive sent e-mail invitations to 16,000 panel
members. Of the 16,000 invitations, 2,049 patients responded
(response rate ¼ 13%). Information on the patients who did not
respond is not available. Of the 2,049 patients who responded,
362 met the inclusion criteria (qualiﬁcation rate ¼ 18%) and 294
consented to participate in the survey. Five patients (1.7%) had no
variations in their responses to the treatment-choicequestions. These
patients chose the same response (MedicineAorMedicine B) in all 10
treatment-choice questions. The lack of variation in responses sug-
gested that thesepatientswerenotpayingattention to the treatment-
choice questions; their responses were deleted from the sample. The
ﬁnal patient sample size used in the analysis was 289.
Table II presents summary statistics for the 289 patients
included in the ﬁnal analysis. The majority of patients were female
(65%), married (63%), and white (99%). The mean [standard devia-
tion (SD)] age was 59 (8.4) years. The majority of patients received
their ﬁrst OA diagnosis from a doctor at least 2 years ago (79%).
Seventy-six percent of patients were currently taking a prescription
medication, and 48% of patients were taking an over-the-counter
medication to treat their OA. The majority of patients did not
have high blood pressure (51%), did not take prescription medica-
tion to treat GI side effects (64%), and had not had a prior heart
attack (94%) or stroke (95%).
Importance weights
Figure 2 shows the estimated importance weights and 95%
conﬁdence intervals (CIs) for the seven attributes. If the CIs do not
overlap for adjacent levels in a particular attribute, the mean
Fig. 2. Importance weights for attribute levels.
Legend: The two vertical arrows demonstrate equivalent changes in importance
weights for the seven attributes. Only relative differences matter when interpreting
importance weights. The differences between adjacent weights indicate the relative
importance of moving from one level of an attribute to an adjacent level of that
attribute. Note: the vertical lines around each mean importance weight denote the 95%
CI about the point estimate.
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of signiﬁcance or better. For example, the mean estimates were
ordered as expected for MI, with better clinical outcomes having
higher estimates; the mean estimates were statistically different
between all the adjacent levels (P < 0.05).
These data may be interpreted in three primary ways. First,
differences between adjacent importance weights indicated the
relative importance of moving from one level of an attribute to an
adjacent level of that attributedthe greater the difference, the
more important the change from one level to the next. Second, the
difference between adjacent importance weights of one attribute
could be compared with the difference between adjacent impor-
tance weights of a different attribute for purposes of understanding
whether the magnitude of the importance of a given change was
comparable across attributes. Third, the vertical distance between
the importance weights for the best and worst levels of any attri-
bute yielded a mean overall importance score, representing theFig. 3. Overall importance scores for attributes.
Legend: (1) Importance of each beneﬁt outcome is the importance of eliminating severe (7
importance of eliminating a 3.0% annual risk. (3) Importance of bleeding ulcer is the imp
importance score denote the 95% CI about the point estimate.importance of that attribute over the entire range of levels included
in the study relative to any other attribute.
With respect to differences between adjacent importance
weights within one beneﬁt attribute, patients attached a greater
importance to moving from mild pain to no pain, (a difference in
importance weights of approximately 1.0 unit) than to reducing
moderate or severe pain by one category. Interestingly, the
importance weights for 75-mm resting pain (generally considered
severe) and 50-mm resting pain (generally considered moderate)
on the visual analog scale (VAS) were not different, indicating that
only improvements that result in resting pain of 50 mm or below
were important to patients. With respect to differences between
adjacent importance weights within one safety attribute, the
importance of reducing MI risk from 3% to 1.5% (a difference in
importance weight of approximately 1.3 units) was the most
important. A similar result was seen for reduction in stroke risk
from 3% to 1.5% (a difference in importance weight of approxi-
mately 1.2 units). With respect to comparisons of the magnitude of
the differences in weights across attributes, Fig. 2 indicates that the
differences in importance weights for a reduction from 75 mm to
25 mm in ambulatory pain and an increase in MI risk from 0.5% to
1.5% were similar, with differences in importance weights of 0.95
and 0.90, respectively. Thus patients’ perceived beneﬁt of a 50-mm
improvement in the ambulatory pain endpoint over this range had
approximately the same value as a 1.0 percentage-point absolute
increase in the perceived risk of an MI. Patients generally attached
greater importance to reducing or eliminating adverse events than
reducing pain. We found no statistical evidence of heterogeneity in
preferences explained by sociodemographic factors or self-
reported severity of OA.
Figure 3 presents the mean overall importance score for each
attribute. In terms of beneﬁt outcomes, patients ranked both
eliminating ambulatory pain and difﬁculty doing daily activities of
75 mm (commonly considered severe) on the VAS as the most
important beneﬁt outcomes (6.32; 95% CI: 5.0e7.6), followed by
eliminating severe resting pain (2.80; 95% CI: 1.8e3.8) and elimi-
nating severe stiffness (2.65; 95% CI: 0.9e4.4). Eliminating ambu-
latory pain of 75 mm thus was approximately 2.3 (6.32/2.80) times
as important as eliminating resting pain of the same magnitude.
Furthermore, incremental changes (3 percentage-point decreases)5 mm on a 100-mm scale) symptoms. (2) Importance of heart attack and stroke is the
ortance of eliminating a 2.5% annual risk. Note: the vertical lines around each mean
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7.3e10.5) were assessed as the most important risk outcomes by
patients. A 2.5-percentage-point incremental change in 1-year
ulcer risk was valued less (3.61; 95% CI: 2.6e4.6).
Risk tolerance
Table III presents the level of treatment-related risks patients
were willing to accept in exchange for various improvements in
ambulatory and resting pain. For example, on average, patients
were willing to accept an increase in bleeding-ulcer risk of
0.7 percentage points (95% CI: 0.3e2.6%) for an improvement in
ambulatory pain from 75 mm to 50 mm. Generally, patients were
willing to accept similar risks for ulcers and strokes within the
ambulatory pain dimension and lower risks for MI. Interestingly,
the acceptable risk associated with a 25-mm reduction in ambu-
latory pain was dependent on the baseline level of ambulatory
pain: patients accepted the greatest acceptable risk of adverse
events when improving from 25 mm to 0 mm, a smaller risk when
improving from 75 mm to 50 mm, and the smallest risk when
improving from 50 mm to 25 mm on the VAS pain scale.
MAR for an improvement in pain score for resting pain also was
dependent on the baseline level of resting pain. However, because
the importance weights for 75-mm resting pain (generally
considered severe) and 50-mm resting pain (generally considered
moderate) were not different, patients were unwilling to accept any
risk in exchange for an improvement in resting pain from 75 mm to
50 mm. However, patients accepted some risk for improvements in
resting pain from 50 mm to 25 mm and greater risk for improve-
ments from 25 mm to 0 mm on the VAS pain scale.
In general, patients were willing to accept larger risks in
exchange for 25-mm improvements in ambulatory pain than for
comparable improvements in resting pain. For example, for an
improvement of 25 mme0 mm, patients on average were willing
to accept an increase in MI risk of 0.8 percentage points (95% CI:
0.4e1.4%) for ambulatory pain and 0.4 percentage points (95% CI:
0.2e0.8%) for resting pain. We found no statistical differences in
patient preferences when considering patient characteristics of
gender, current prescription medication, hypertension, or time
since diagnosis.
Figure 4 demonstrates the relationship between the relative
importance of improvements in pain and the MAR patients would
bewilling to accept to achieve each level of pain reduction. A higher
level of relative importance for a given pain reduction is associated
with a higher relative MAR for a given adverse-event risk. For
example, the highest relative importance is associated with
a reduction in ambulatory pain from 25 mm (mild) to 0 mm (none)
and the lowest relative importance is associated with a reduction in
resting pain from 75 mm (severe) to 50 mm (moderate). Likewise
the highest and lowest MARs for any adverse-event risk is achievedTable III
Ulcer, heart-attack, and stroke risks patients are willing to accept for improvements in P
Improvement in pain Bleeding-ulcer risk
Pain while moving around 1 h after taking the medicine (ambulatory pain)
75 mme50 mm 0.74% (0.32%, 2.61%)
50 mme25 mm 0.35% (0.02%, 0.88%)
25 mme0 mm 1.99% (0.70%, 5.03%)
Pain while sitting, lying down, or sleeping 1 h after taking the medicine (resting pain)
75 mme50 mm 0.00% (N/A)
50 mme25 mm 0.31% (0.03%, 0.71%)
25 mme0 mm 0.68% (0.36%, 1.29%)
N/A ¼ not applicable.
* This table presents themean risks (95% CIs) patients were willing to accept in exchang
patients were willing to accept an increase in bleeding-ulcer risk of 0.7% (0.3e2.6%) forfor reductions of ambulatory pain from mild to none and resting
pain from severe to moderate, respectively. Figure 4 also demon-
strates that for any given improvement in pain, less important risks
are associated with higher risk tolerance. Speciﬁcally, bleeding-
ulcer risk is less important than either of the cardiovascular risks
and thus is associated with greater risk tolerance. Among the
cardiovascular risks, patients have greater tolerance for stroke risks
than for heart-attack risks. However, the differences in MARs for
heart-attack and stroke risk generally are smaller than the differ-
ence in MARs between the cardiovascular risks and the risk of
bleeding ulcer.
Discussion
Our study has three main ﬁndings. First, the most important
beneﬁt attributes were reducing ambulatory pain and difﬁculty
doing daily activities, especially in eliminating mild pain. Second,
patients generally attached greater importance to eliminating the
risks of adverse events than in reducing pain. Third, risk tolerance
varied according to the baseline level and type of symptom relief.
The results of our study have two main clinical implications. First,
because OA patients value ambulatory pain and resting pain
differently, WOMAC scores may not capture the full range of pain
attributes important to OA patients. Second, physicians should
discuss the different types of beneﬁts and risks of medications with
OA patients to identify the treatment that is consistent with each
patient’s preferences.
Several studies have focused on patient preferences in
OA2527,39 and rheumatoid arthritis4042 treatments. Ratcliffe
et al.39 concluded that the level of joint aches, level of physical
mobility, and treatment-related serious side-effect risks were
most inﬂuential to OA patient treatment preferences. Fraenkel
et al.25 found that preferences for COX-2 inhibitors were stronger
when the GI risks were eliminated rather than reduced, even if
the absolute risk reduction was the same in either instance.
Fraenkel et al.26 found that older patients with OA in the knees
were willing to accept a lower treatment efﬁcacy in exchange for
a lower risk of adverse events. Fraenkel and Fried27 concluded
that patients with OA in the knees preferred exercise to
prescription treatments due to unwillingness to accept the risks
of adverse events. Similar to our study, Kopec et al.17 estimated
risk tolerance among patients with OA. Speciﬁcally, Kopec et al.17
used a probabilistic threshold technique to estimate MAR of heart
attack/stroke, stomach bleed, ﬂuid retention, high blood pressure,
and dyspepsia for different improvements in total WOMAC score.
To our knowledge, our study provides the ﬁrst systematic evalu-
ation, using a discrete-choice experiment to quantify patients’
willingness to trade off among improvements in multiple
symptom domains and multiple treatment-related risks for
NSAIDs used in the management of OA.ain*
Heart-attack risk Stroke risk
0.43% (0.18%, 0.91%) 0.73% (0.29%, 1.19%)
0.20% (0.01%, 0.59%) 0.38% (0.03%, 0.94%)
0.80% (0.36%, 1.38%) 1.09% (0.60%, 1.62%)
0.00% (N/A) 0.00% (N/A)
0.18% (0.02%, 0.47%) 0.34% (0.03%, 0.34%)
0.39% (0.18%, 0.81%) 0.68% (0.28%, 1.13%)
e for various improvements in ambulatory and resting pain. For example, on average,
an improvement in ambulatory pain of 75 mme50 mm (severe to moderate).
Fig. 4. Relative importance of improvements in pain and risk tolerance.
*Relative importance of improvements in ambulatory pain and resting pain along with the corresponding MAR estimates for three adverse-event risks. Note: the vertical lines
around each mean estimate denote the 95% CI about the point estimate.
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clearly weighed ambulatory pain as being more important than
resting pain. Perhaps the most telling result that emphasizes this
importance was patients’ willingness to accept four times the risk
of MI to achieve a 25-mm reduction in ambulatory pain vs a 25-mm
reduction in resting pain. This likely reﬂects the impact ambulatory
pain has on a patients’ ability to do daily activities and is consistent
with newer instruments under development43. Patient preferences
and particularly views on risk-beneﬁt ratios are important when
considering drug development programs and outcomes both in
clinical trials and in clinical practice. Future clinical trials and drug
development programs should focus on patients’ current level of
OA pain and their willingness to accept different intervention
strategies as part of the inclusion criteria.
Although discrete-choice methods are widely used in health
economics to elicit preferences, they have limitations. One limita-
tion is that patients evaluate hypothetical treatments. Constructed
treatment-choice questions are intended to simulate possible
decisions but do not have the same clinical, ﬁnancial, or emotional
consequences of actual decisions. Thus, differences can arise
between stated and actual choices. We attempted to minimize such
potential differences by offering alternatives that mimicked current
real-world tradeoffs as closely as possible.
We did not know how many members of the Harris Interactive
chronic-illness panel opened the e-mail invitation but did not
respond. Nor did we know the characteristics of nonrespondents,
patients who did not meet the inclusion criteria, or patients who
did not consent to participate. Thus, we cannot be certain that theresults of this study are generalizable to the overall population of
patients in the UK, especially because 99% of the OA patients in our
sample were white. However, because we found no evidence that
sociodemographic characteristics explained differences in patient
preferences, we do not feel that this likely biased the results of this
study. Rather than using actual physician records, we used patients’
self-report of a physician’s diagnosis of OA. However, previous
studies have shown that self-reported physician-level diagnoses of
OA have a high degree of validity, with a concordance of 86.9%
compared with primary care records44,45. We also did not collect
data on the type of OA nor on the patients’ history of joint surgeries
which may have been helpful in characterizing our patient pop-
ulation. In addition, to estimate maximum risk tolerance, we asked
patients to evaluate ranges of risks that were wider than those
commonly seen in clinical practice. To quantify risk tolerance
relative to the relevant level of stroke risk, we linearly interpolated
between two risk levels included in the survey. Because risk pref-
erences between these levels may not be linear, our estimate of
patient risk preferences for a 2.5% risk of stroke is an approximation
based on the assumption that risks are linear between these two
levels.
In conclusion, this study provides evidence that patient prefer-
ences clearly are affected by the type of beneﬁt and risk being
considered and that OA patients are willing to accept greater risks
for improvement in ambulatory pain than in resting pain. These
types of studies provide insight for researchers, clinicians, and
regulators when considering a treatment’s effects on various
outcomes from both a beneﬁt and a risk perspective.
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